We offer much greater flexibility [than larger firms]; as a small company there is direct contact with the project’s leaders and management and that allows us…
In Conversation
At the beginning of my career, over 20 years ago, there were no market access issues, as the reimbursement and pricing system was set up around…
Stakeholders are aware that medical devices complement medicines and we are in constant discussion with the government, regulators, and payers to communicate what medical technologies are…
Without any doubt, my biggest achievement at EastHORN is building a strong team that I can always rely on. Once you have found the perfect team,…
Colorectal ... is the second most predominant cancer in the Czech Republic, and an area with a high unmet medical need. Our combo therapy represents a…
What we can work to improve is the first step in a patient’s journey through the system. Currently, there are many barriers, and patients do not…
We are highly competitive in terms of patient recruitment. We have some of the highest numbers of patients in clinical trials per total number of patients…
We live in a time when value is becoming increasingly important. We feel that healthcare providers should continue to think about the bigger picture and overall…
In the future, I would like to see more gene therapies being conducted in the country. This is the future of research and treatment
My main priority is to merge these unique sets of experiences from different countries and bring everyone together on the same page, so that every problem…
As part of the AIFP, Sanofi is very much involved in trying to shape the environment in a way that provides a better frame and visibility…
Compared to other countries, we have a very dense network of specialized clinics with high-quality clinical equipment, where all administrative work is completed on advanced service…
